CN105456277B - 灵芝三萜酸活性部位在制备降血脂保健品和药物中的应用 - Google Patents
灵芝三萜酸活性部位在制备降血脂保健品和药物中的应用 Download PDFInfo
- Publication number
- CN105456277B CN105456277B CN201510933865.8A CN201510933865A CN105456277B CN 105456277 B CN105456277 B CN 105456277B CN 201510933865 A CN201510933865 A CN 201510933865A CN 105456277 B CN105456277 B CN 105456277B
- Authority
- CN
- China
- Prior art keywords
- acid
- ethyl acetate
- ganoderma lucidum
- ganodenic
- dry powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002253 acid Substances 0.000 title claims abstract description 161
- 230000000694 effects Effects 0.000 title claims abstract description 76
- 210000004369 blood Anatomy 0.000 title claims abstract description 29
- 239000008280 blood Substances 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 229940079593 drug Drugs 0.000 title claims abstract description 13
- 230000036541 health Effects 0.000 title claims abstract description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 48
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 46
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 46
- 108090000790 Enzymes Proteins 0.000 claims abstract description 32
- 102000004190 Enzymes Human genes 0.000 claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 31
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000007788 liquid Substances 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000463 material Substances 0.000 claims abstract description 16
- 238000000605 extraction Methods 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 12
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 claims abstract description 11
- 229930182735 Ganoderic acid Natural products 0.000 claims abstract description 11
- 239000002024 ethyl acetate extract Substances 0.000 claims abstract description 11
- 239000004519 grease Substances 0.000 claims abstract description 11
- 238000010828 elution Methods 0.000 claims abstract description 7
- 238000000926 separation method Methods 0.000 claims abstract description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000001816 cooling Methods 0.000 claims abstract description 6
- 230000009849 deactivation Effects 0.000 claims abstract description 6
- 238000007689 inspection Methods 0.000 claims abstract description 6
- 239000003208 petroleum Substances 0.000 claims abstract description 6
- 239000000741 silica gel Substances 0.000 claims abstract description 6
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 6
- 238000004809 thin layer chromatography Methods 0.000 claims abstract description 6
- 238000010298 pulverizing process Methods 0.000 claims abstract description 5
- 229940088598 enzyme Drugs 0.000 claims description 29
- 108010059892 Cellulase Proteins 0.000 claims description 7
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 claims description 7
- 229940106157 cellulase Drugs 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 5
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 2
- 238000005086 pumping Methods 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 9
- 238000003810 ethyl acetate extraction Methods 0.000 abstract description 8
- 238000000967 suction filtration Methods 0.000 abstract 1
- 241000699684 Meriones unguiculatus Species 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 15
- 208000031226 Hyperlipidaemia Diseases 0.000 description 14
- 150000003626 triacylglycerols Chemical class 0.000 description 12
- 241000699694 Gerbillinae Species 0.000 description 10
- 108010028554 LDL Cholesterol Proteins 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000207961 Sesamum Species 0.000 description 7
- 235000003434 Sesamum indicum Nutrition 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 239000003480 eluent Substances 0.000 description 6
- -1 lanostane triterpenes Chemical class 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002798 spectrophotometry method Methods 0.000 description 4
- 150000003648 triterpenes Chemical class 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 238000013232 NAFLD rodent model Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 101000904460 Encephalitozoon cuniculi (strain GB-M1) Probable glycerol-3-phosphate dehydrogenase Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241001489090 Ganoderma japonicum Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000013231 NASH rodent model Methods 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 description 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
组别 | 动物数 | 初始体重(g) | 中期体重(g) | 末期体重(g) |
空白对照组 | 10 | 51.09±2.76 | 59.87±5.11 | 66.23±3.72 |
模型对照组 | 10 | 49.21±5.17 | 62.10±6.18 | 67.28±2.76 |
灵芝三萜酸30mg/kg | 10 | 53.17±3.23 | 58.99±1.66 | 71.22±2.49 |
灵芝三萜酸70mg/kg | 10 | 51.33±3.96 | 61.22±2.84 | 68.58±3.47 |
灵芝三萜酸110mg/kg | 10 | 52.87±6.92 | 60.38±3.27 | 73.12±5.81 |
灵芝三萜酸150mg/kg | 10 | 50.37±4.63 | 58.99±1.20 | 69.43±2.17 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510933865.8A CN105456277B (zh) | 2015-12-14 | 2015-12-14 | 灵芝三萜酸活性部位在制备降血脂保健品和药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510933865.8A CN105456277B (zh) | 2015-12-14 | 2015-12-14 | 灵芝三萜酸活性部位在制备降血脂保健品和药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105456277A CN105456277A (zh) | 2016-04-06 |
CN105456277B true CN105456277B (zh) | 2018-07-31 |
Family
ID=55594743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510933865.8A Active CN105456277B (zh) | 2015-12-14 | 2015-12-14 | 灵芝三萜酸活性部位在制备降血脂保健品和药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105456277B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106722875A (zh) * | 2016-12-07 | 2017-05-31 | 盐城工学院 | 一种灵芝三萜的提取方法及灵芝保健品 |
CN108802255B (zh) * | 2018-06-15 | 2020-09-11 | 福建仙芝楼生物科技有限公司 | 测定复方制剂中灵芝三萜类成分含量的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772448A (zh) * | 2012-08-15 | 2012-11-14 | 苏州菩芸生物科技有限公司 | 灵芝三萜提取方法 |
CN104761612B (zh) * | 2015-02-03 | 2016-11-23 | 安发(福建)生物科技有限公司 | 灵芝三萜酸提取分离工艺方法 |
-
2015
- 2015-12-14 CN CN201510933865.8A patent/CN105456277B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN105456277A (zh) | 2016-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101836725A (zh) | 红曲渣产品在制备降血脂保健食品方面的应用 | |
CN103120228A (zh) | 一种调节血脂的黑茶组合物及制备方法 | |
CN105456277B (zh) | 灵芝三萜酸活性部位在制备降血脂保健品和药物中的应用 | |
CN105663444A (zh) | 一种复方免疫增强及抗衰老剂及其制备方法 | |
CN1330670C (zh) | 玉竹多糖的提取方法、药物制剂制备方法及其用途 | |
JP5622222B2 (ja) | 血脂降下組成物及びその使用 | |
CN103451084B (zh) | 一种解酒保肝醋及其制备方法与应用 | |
CN104055947B (zh) | 一种含有葡萄提取物的中药组合物及制备方法 | |
CN105713942B (zh) | 西兰花多肽活性组分及其制备方法和应用 | |
CN101849950A (zh) | 救必应酸在制备调血脂的药物中的应用 | |
CN1175758C (zh) | 一种从枣中分离提取环核苷酸糖浆、膳食纤维和枣蜡的方法 | |
JP4743947B2 (ja) | 脂質代謝改善組成物 | |
CN105193824B (zh) | 一种灵芝三萜酸活性部位及其制备方法和应用 | |
CN104940178A (zh) | 治疗高脂血症、动脉粥样硬化的药物及制备方法和应用 | |
CN101804083B (zh) | 松花粉及其提取物在治疗炎症性肠病中的用途及该提取物的制备方法 | |
CN109699887B (zh) | 一种牡丹籽油降血脂软胶囊及其制备方法 | |
CN107028965A (zh) | 芫根苷或其衍生物在制备降脂药物中的应用和产品 | |
CN106822071B (zh) | 一种用于治疗冠心病、高脂血症的中药有效部位、制备方法及从中分离有效成分的方法 | |
CN106620344A (zh) | 一种具有降血脂功效的组合物及其制备方法 | |
CN113713016B (zh) | 代代花在制备改善脂肪肝药物中的应用 | |
CN100374121C (zh) | 分蘖葱头提出物及其应用 | |
CN107897267A (zh) | 一种保健月饼及其制备方法 | |
CN110327392B (zh) | 一种榅桲-罗勒总黄酮组合物及在动脉粥样硬化中的应用 | |
CN108271971A (zh) | 一种具有降血脂作用的中药醋蛋液及其制备方法 | |
CN102319273A (zh) | 北美盐角草活性总皂苷提取物及其制备方法和瘦身减肥的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 310013 No. 182 Tianmu Mountain Road, Zhejiang, Hangzhou Patentee after: HANGZHOU MEDICAL College Address before: 310013 No. 182 Tianmu Mountain Road, Zhejiang, Hangzhou Patentee before: ZHEJIANG ACADEMY OF MEDICAL SCIENCES |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230607 Address after: 310000 No. 182, Tianmushan Road, Xihu District, Hangzhou City, Zhejiang Province Patentee after: Zhejiang Pufa Technology Development Center Address before: 310013 No. 182 Tianmu Mountain Road, Zhejiang, Hangzhou Patentee before: HANGZHOU MEDICAL College |
|
TR01 | Transfer of patent right |